Vitamin B6 Inhibits Activity of Adenylosuccinate Synthetase and Growth of Reference and Clinical, Antibiotic-resistant Strains

Overview

Journal J Enzyme Inhib Med Chem

Specialty Biochemistry

Date 2024 Aug 16

PMID 39149761

Authors

Marta Ilona Wojtys

Weronika Maksymiuk

Marta Narczyk

Ante Bubic

Ivana Lescic Asler

Pawel Krzyzek

Grazyna Gosciniak

Elzbieta Katarzyna Jagusztyn-Krynicka

Agnieszka Bzowska

Affiliations

Soon will be listed here.

Abstract

The current therapies against gastric pathogen are ineffective in over 20% of patients. Enzymes belonging to the purine salvage pathway are considered as novel drug targets in this pathogen. Therefore, the main aim of the current study was to determine the antibacterial activity of pyridoxal 5'-phosphate (PLP), an active form of vitamin B6, against reference and clinical strains of . Using a broad set of microbiological, physicochemical (UV absorption, LC-MS, X-ray analysis) and experiments, we were able to prove that PLP inhibits adenylosuccinate synthetase (AdSS) from by the competition with GTP (IC ∼30 nM). This behaviour was attributed to formation of a Schiff base with a lysine residue (a covalent bond with Lys322 in the GTP binding site of AdSS) and was potentiated by the presence of vitamin C. This antibacterial activity of PLP gives hope for its future use against .

References

Makobongo M, Kovachi T, Gancz H, Mor A, Merrell D . In vitro antibacterial activity of acyl-lysyl oligomers against Helicobacter pylori. Antimicrob Agents Chemother. 2009; 53(10):4231-9. PMC: 2764229. DOI: 10.1128/AAC.00510-09. View

Huang C, Tsai K, Tsai T, Hsu P . Update on the first-line treatment for infection - a continuing challenge from an old enemy. Biomark Res. 2017; 5:23. PMC: 5505131. DOI: 10.1186/s40364-017-0103-x. View

Parra M, Stahl S, Hellmann H . Vitamin B₆ and Its Role in Cell Metabolism and Physiology. Cells. 2018; 7(7). PMC: 6071262. DOI: 10.3390/cells7070084. View

Sjomina O, Pavlova J, Niv Y, Leja M . Epidemiology of Helicobacter pylori infection. Helicobacter. 2018; 23 Suppl 1:e12514. DOI: 10.1111/hel.12514. View

Zhou Y, Joubran C, Miller-Vedam L, Isabella V, Nayar A, Tentarelli S . Thinking outside the "bug": a unique assay to measure intracellular drug penetration in gram-negative bacteria. Anal Chem. 2015; 87(7):3579-84. DOI: 10.1021/ac504880r. View

Ferrero R, Cussac V, Courcoux P, Labigne A . Construction of isogenic urease-negative mutants of Helicobacter pylori by allelic exchange. J Bacteriol. 1992; 174(13):4212-7. PMC: 206198. DOI: 10.1128/jb.174.13.4212-4217.1992. View

Rudolph F, FROMM H . Initial rate studies of adenylosuccinate synthetase with product and competitive inhibitors. J Biol Chem. 1969; 244(14):3832-9. View

Katan M . [How much vitamin B6 is toxic?]. Ned Tijdschr Geneeskd. 2005; 149(46):2545-6. View

Bubic A, Narczyk M, Petek A, Wojtys M, Maksymiuk W, Wielgus-Kutrowska B . The pursuit of new alternative ways to eradicate Helicobacter pylori continues: Detailed characterization of interactions in the adenylosuccinate synthetase active site. Int J Biol Macromol. 2022; 226:37-50. DOI: 10.1016/j.ijbiomac.2022.12.001. View

10.

. Schistosomes, liver flukes and Helicobacter pylori. IARC Monogr Eval Carcinog Risks Hum. 1994; 61:1-241. PMC: 7681621. View

11.

McCoy A, Grosse-Kunstleve R, Adams P, Winn M, Storoni L, Read R . Phaser crystallographic software. J Appl Crystallogr. 2009; 40(Pt 4):658-674. PMC: 2483472. DOI: 10.1107/S0021889807021206. View

12.

Bonomo R . Cefiderocol: A Novel Siderophore Cephalosporin Defeating Carbapenem-resistant Pathogens. Clin Infect Dis. 2019; 69(Suppl 7):S519-S520. PMC: 6853757. DOI: 10.1093/cid/ciz823. View

13.

Fitzpatrick T, Amrhein N, Kappes B, Macheroux P, Tews I, Raschle T . Two independent routes of de novo vitamin B6 biosynthesis: not that different after all. Biochem J. 2007; 407(1):1-13. DOI: 10.1042/BJ20070765. View

14.

Vagin A, Teplyakov A . Molecular replacement with MOLREP. Acta Crystallogr D Biol Crystallogr. 2010; 66(Pt 1):22-5. DOI: 10.1107/S0907444909042589. View

15.

Krzyzek P, Paluch E, Gosciniak G . Synergistic Therapies as a Promising Option for the Treatment of Antibiotic-Resistant . Antibiotics (Basel). 2020; 9(10). PMC: 7599531. DOI: 10.3390/antibiotics9100658. View

16.

Winn M, Ballard C, Cowtan K, Dodson E, Emsley P, Evans P . Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol Crystallogr. 2011; 67(Pt 4):235-42. PMC: 3069738. DOI: 10.1107/S0907444910045749. View

17.

Roszczenko-Jasinska P, Wojtys M, Jagusztyn-Krynicka E . Helicobacter pylori treatment in the post-antibiotics era-searching for new drug targets. Appl Microbiol Biotechnol. 2020; 104(23):9891-9905. PMC: 7666284. DOI: 10.1007/s00253-020-10945-w. View

18.

Makowska-Grzyska M, Kim Y, Maltseva N, Osipiuk J, Gu M, Zhang M . A novel cofactor-binding mode in bacterial IMP dehydrogenases explains inhibitor selectivity. J Biol Chem. 2015; 290(9):5893-911. PMC: 4342496. DOI: 10.1074/jbc.M114.619767. View

19.

Rownicki M, Wojciechowska M, Wierzba A, Czarnecki J, Bartosik D, Gryko D . Vitamin B as a carrier of peptide nucleic acid (PNA) into bacterial cells. Sci Rep. 2017; 7(1):7644. PMC: 5550456. DOI: 10.1038/s41598-017-08032-8. View

20.

Murshudov G, Skubak P, Lebedev A, Pannu N, Steiner R, Nicholls R . REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr D Biol Crystallogr. 2011; 67(Pt 4):355-67. PMC: 3069751. DOI: 10.1107/S0907444911001314. View